HK1093523A1 - Lentiviral vectors for the preparation of immunotherapeutical compositions - Google Patents

Lentiviral vectors for the preparation of immunotherapeutical compositions

Info

Publication number
HK1093523A1
HK1093523A1 HK06111332.8A HK06111332A HK1093523A1 HK 1093523 A1 HK1093523 A1 HK 1093523A1 HK 06111332 A HK06111332 A HK 06111332A HK 1093523 A1 HK1093523 A1 HK 1093523A1
Authority
HK
Hong Kong
Prior art keywords
retroviral
response
vector
preparation
cis
Prior art date
Application number
HK06111332.8A
Other languages
English (en)
Inventor
Pierre Charneau
Hueseyin Firat
Veronique Zennou
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of HK1093523A1 publication Critical patent/HK1093523A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HK06111332.8A 1999-10-11 2003-01-17 Lentiviral vectors for the preparation of immunotherapeutical compositions HK1093523A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99402492A EP1092779B1 (de) 1999-10-11 1999-10-11 Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
HK03100475.1A HK1049861B (zh) 1999-10-11 2003-01-17 製備免疫治療組合物的慢病毒載體

Publications (1)

Publication Number Publication Date
HK1093523A1 true HK1093523A1 (en) 2007-03-02

Family

ID=8242139

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06111332.8A HK1093523A1 (en) 1999-10-11 2003-01-17 Lentiviral vectors for the preparation of immunotherapeutical compositions
HK03100475.1A HK1049861B (zh) 1999-10-11 2003-01-17 製備免疫治療組合物的慢病毒載體

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK03100475.1A HK1049861B (zh) 1999-10-11 2003-01-17 製備免疫治療組合物的慢病毒載體

Country Status (15)

Country Link
US (3) US7968332B2 (de)
EP (4) EP1092779B1 (de)
JP (2) JP4663943B2 (de)
CN (2) CN1379820B (de)
AT (3) ATE449858T1 (de)
AU (3) AU785060B2 (de)
CA (1) CA2387182C (de)
CY (4) CY1105149T1 (de)
DE (3) DE69941703D1 (de)
DK (4) DK2169073T3 (de)
ES (4) ES2337429T3 (de)
HK (2) HK1093523A1 (de)
IL (2) IL148901A0 (de)
PT (4) PT2169073E (de)
WO (1) WO2001027300A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
PT2169073E (pt) 1999-10-11 2014-02-20 Pasteur Institut Vectores para a preparação de composições imunoterapêuticas
DK1792997T3 (da) 1999-10-12 2012-01-30 Inst Nat Sante Rech Med Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (de) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor-produktionssystemen
KR20040054699A (ko) 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP1712241A1 (de) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Intratumoral applizierbare Zusammensetzung zur Krebsbehandlung
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1739092A1 (de) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidische Antagonisten von Klasse III Semaphorin/Neuropilin Komplexen
EP1748067A1 (de) 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
WO2007054814A1 (en) 2005-11-14 2007-05-18 Centre National De La Recherche Scientifique - Cnrs Inhibitors of parp activity and uses thereof
CA2723320C (en) 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
AU2008285224B2 (en) * 2007-08-03 2015-01-22 Centre National De La Recherche Scientifique (Cnrs) Lentiviral gene transfer vectors and their medicinal applications
DK2385107T3 (en) 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vector-based immunological compounds against malaria
EP2666477A1 (de) 2012-05-23 2013-11-27 Theravectys Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
JP6215223B2 (ja) 2011-12-09 2017-10-18 アンスティテュ・パストゥール マルチプレックス免疫スクリーニングアッセイ
WO2014016383A2 (en) 2012-07-25 2014-01-30 Theravectys Glycoproteins for pseudotyping lentivectors
EP3009144A1 (de) 2014-10-15 2016-04-20 Theravectys Lentivirale Vektoren zur Induzierung von CD4+- und+CD8+-Immunreaktionen bei der Impfung von Menschen
WO2015063708A1 (en) 2013-10-31 2015-05-07 Theravectys LENTIVIRAL VECTORS FOR INDUCING CD4+ and CD8+ IMMUNE RESPONSES IN VACCINATION OF HUMANS INFECTED WITH HIV-1
EP3087188A1 (de) 2013-12-23 2016-11-02 Theravectys Lyophilisierte lentiviren-vektor-partikel, zusammensetzungen daraus und verfahren
BR112016017242A2 (pt) 2014-01-27 2017-10-03 Theravectys Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
CN107531800B (zh) 2014-07-25 2021-08-10 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
EP3211003A1 (de) 2016-02-24 2017-08-30 Institut Pasteur T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon
EP3276006A1 (de) 2016-07-27 2018-01-31 Theravectys Lentivirale vektoren zur expression von hepatitis-b-virus (hbv)-antigenen
EP3357504A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung
EP3357506A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt
WO2019009979A1 (en) 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CSH-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR DISEASE THERAPY
EP3697809A1 (de) 2017-10-20 2020-08-26 Institut Curie Für rush angepasste dap10/12-basierte cars
WO2019077164A1 (en) 2017-10-20 2019-04-25 Institut Curie CROCHET FUSION PROTEIN FOR REGULATING THE CELLULAR TRAFFIC OF A TARGET PROTEIN
CN108118070A (zh) * 2018-01-15 2018-06-05 南京驯鹿医疗技术有限公司 一种慢病毒制备方法
CN108588028B (zh) * 2018-04-26 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种靶向cdkn2a的cic细胞模型及其制备方法
CA3136252A1 (en) 2019-05-10 2020-11-19 Francesca DI NUNZIO Live imaging system to visualize the retro-transcribed viral dna genome
WO2021234110A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
AU2021308424A1 (en) 2020-07-15 2023-02-09 Institut Pasteur SARS-CoV-2 immunogenic compositions, vaccines, and methods
WO2022167831A1 (en) 2021-02-02 2022-08-11 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
AU2021358957A1 (en) 2020-10-07 2023-06-08 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
EP3984548A1 (de) 2020-10-16 2022-04-20 Institut Pasteur Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren
EP4229090A1 (de) 2020-10-16 2023-08-23 Université d'Aix-Marseille Anti-gpc4-einzeldomänenantikörper
IL304031A (en) 2021-01-14 2023-08-01 Inst Curie Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
WO2022189656A1 (en) 2021-03-12 2022-09-15 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
AU2022386715A1 (en) 2021-11-15 2024-05-16 Institut Pasteur Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024023135A1 (en) 2022-07-27 2024-02-01 Theravectys Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024084041A2 (en) 2022-10-21 2024-04-25 Institut Pasteur Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651311B2 (en) * 1988-03-21 1994-07-21 Chiron Corporation Recombinant retroviruses
GB9213559D0 (en) * 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
JPH06261764A (ja) 1993-02-17 1994-09-20 Wisconsin Alumni Res Found 混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997032983A1 (en) * 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
EP0991771A2 (de) * 1997-03-06 2000-04-12 Klaus Überla Vektoren, die auf lentiviren basieren und vektorsysteme
EP1007716A4 (de) 1997-04-17 2000-06-14 Univ California Verwendung von lentiviralen vektoren zur antigeneinführung in dendritischezellen
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
ES2217585T3 (es) * 1997-10-10 2004-11-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
JP2002507544A (ja) * 1997-11-14 2002-03-12 ユーロ−セルティーク，エス．エイ． 抗イディオタイプ応答を引き出す能力が増強された改変型の抗体
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US6555342B1 (en) * 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
PT2169073E (pt) 1999-10-11 2014-02-20 Pasteur Institut Vectores para a preparação de composições imunoterapêuticas
DK1792997T3 (da) 1999-10-12 2012-01-30 Inst Nat Sante Rech Med Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
AU2006252062B2 (en) 2010-04-22
US7968332B2 (en) 2011-06-28
DE60028066T2 (de) 2007-01-18
EP2169073A1 (de) 2010-03-31
EP1222300A1 (de) 2002-07-17
ATE441721T1 (de) 2009-09-15
AU1143501A (en) 2001-04-23
CA2387182A1 (en) 2001-04-19
US8349606B2 (en) 2013-01-08
DE60028066D1 (de) 2006-06-22
CA2387182C (en) 2010-12-21
EP1650309A1 (de) 2006-04-26
DK1092779T3 (da) 2010-02-15
PT1222300E (pt) 2006-09-29
DK2169073T3 (da) 2014-02-10
AU2010203111B2 (en) 2012-01-19
DE69941703D1 (de) 2010-01-07
CY1110551T1 (el) 2015-04-29
JP2011078420A (ja) 2011-04-21
JP4663943B2 (ja) 2011-04-06
US8652807B2 (en) 2014-02-18
DK1650309T3 (da) 2009-11-30
EP1092779A1 (de) 2001-04-18
AU2006252062A1 (en) 2007-01-18
HK1049861A1 (en) 2003-05-30
IL148901A0 (en) 2002-09-12
PT2169073E (pt) 2014-02-20
HK1049861B (zh) 2006-12-22
CN1840204A (zh) 2006-10-04
EP2169073B1 (de) 2013-11-13
AU785060B2 (en) 2006-09-14
IL204703A0 (en) 2010-11-30
WO2001027300A1 (en) 2001-04-19
EP1650309B1 (de) 2009-09-02
EP1222300B1 (de) 2006-05-17
JP5265643B2 (ja) 2013-08-14
ES2332930T3 (es) 2010-02-15
CN1840204B (zh) 2011-09-07
ES2262545T3 (es) 2006-12-01
CY1110611T1 (el) 2015-04-29
PT1092779E (pt) 2010-01-19
AU2010203111A1 (en) 2010-08-12
CN1379820A (zh) 2002-11-13
ATE449858T1 (de) 2009-12-15
US20110250650A1 (en) 2011-10-13
US20130157357A1 (en) 2013-06-20
ES2337429T3 (es) 2010-04-23
DE60042903D1 (de) 2009-10-15
EP1092779B1 (de) 2009-11-25
JP2003511080A (ja) 2003-03-25
CY1114819T1 (el) 2016-12-14
DK1222300T3 (da) 2006-09-18
ATE326541T1 (de) 2006-06-15
ES2447115T3 (es) 2014-03-11
CY1105149T1 (el) 2010-03-03
PT1650309E (pt) 2009-11-18
CN1379820B (zh) 2011-04-13
US20040081636A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
HK1049861A1 (en) Lentiviral vectors for preparation of immunotherapeutical compositions
EP0878545A3 (de) OspA Proteine von Borrelia Burgdorferi Untergruppen , dafür kodierende Gene sowie Impfstoffe
EP1084261B8 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
EP0837928A4 (de) Zusammensetzungen aus rekombinierten poxvirus-cytomegalovirus und ihre verwendung
CA2253636A1 (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
GEP20032902B (en) Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV
NZ334811A (en) Strain selection of pneumococcal surface proteins
EP1652857A3 (de) Fusionsprotein des regulatorische/akzessorische HIV Proteine
EP1409694A4 (de) Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
WO2004035799A3 (de) Virale vektoren und deren verwendung für die gentherapie
EP0775746A3 (de) Impfstoff gegen Geflügelkokzidose
PT831899E (pt) Composições de poxvírus-calicivírus recombinantes e suas utilizações
ZA961349B (en) Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications
EP0801575A4 (de) Retrovirale vektoren zur expression in embryonalen zellen
EP0832266A4 (de) Orale verabreichung von vektoren, die vom adenoassoziierten virus abgeleitet sind
EP1840209A3 (de) Adeno-assoziierten Virusvektoren und deren Verwendung.
WO2001095946A3 (en) Combination product for carrying out a cytotoxic treatment in a mammal
WO2005027844A3 (en) Dna vaccine compositions and methods of use
WO1999002724A3 (en) Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO1999014333A3 (en) Improved method of production of pneumococcal surface proteins
ES2008391A6 (es) Un metodo para producir isopenicilina n sintetasa.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20201009